You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Non-Surgical Management of Advanced Hepatocellular Carcinoma

ID: GL 2-24 mai 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
B.M. Meyers, , J. Knox,, R. Cosby,, R. Beecroft,, K. Chan,, N. Coburn,, J. Feld,, D. Jonker,, A. Mahmud,, J. Ringash, and the Gastrointestinal Disease Site Group

Guideline Objective

The objective of this guideline is to make recommendations regarding the non-surgical treatment of advanced hepatocellular carcinoma (HCC).

Patient Population

These recommendations apply to adults with locally advanced and advanced HCC, Barcelona Clinic Liver Cancer Stage B and higher, who are not suitable for transplant or surgery.

Intended Guideline Users

Intended users of the guideline are clinicians involved in the care of patients who have HCC; specifically, medical oncologists, radiation oncologists, interventional radiologists, hepatologists, and surgical oncologists.

Research Questions

  1. What are benefits of other local therapies (transarterial ethanol ablation [TEA], bland transarterial embolization [TAE], radiofrequency ablation [RFA], transarterial radioembolization [TARE], stereotactic body radiation therapy [SBRT] and drug eluting bead transarterial chemoembolization [DEB-TACE]) versus transarterial chemoembolization (TACE)?
  2. What is the benefit of the addition of sorafenib to local therapies (TEA, TAE, RFA, TARE, SBRT, TACE, DEB-TACE)
  3. What is the benefit of other systemic treatment regimens versus sorafenib?
  4. What is the benefit of the eradication of viral hepatitis (HCV and/or HBV) in patients with advanced HCC?
  5. What is the benefit of second-line systemic therapy following sorafenib?
  6. Is there a survival difference in HCV populations compared with HBV populations compared with non-viral populations when treated with sorafenib?
  7. Is there a survival difference in HCV populations compared with HBV populations compared with non-viral populations when treated with TACE, TAE, or TEA?
pdf download Summary (PDF) (227.06 Ko)
pdf download Full Report (PDF) (1.37 Mo)